Rusty, a scholarly analysis. Hope it is effective to the benefit of Maine himself and he sees this as an expression of your true compassion.
The Republicans sitting in the Congress are primarily the culprits who help hedgies and banks to commit more such crimes so that they can fatten their campaign funds!! The WS dogs are then always ready to eat others' lunch.
He is probably a double-faced guy, who is privately says something more meaningful but, publicly, lies. After all he is a WS manipulator!!
It's just WS dogs trying to bring the SP down so that they can cover their short positions cheaply. And, the MM is trying to increase his business because more trades take place more money he makes. Both know very well the psychology of monkey traders and are playing their game to maximize their gain. None of these vermins can change the fact that IMET will succeed brilliantly. Just sit and relax.
Keep, look at the down-thumbs you get despite speaking the truth!! This board is full of shorts and bashers who do not like any news or thoughts that challenges their trades!! These vermins think that bashing on this board will make the SP go down as they want!! What a dream they all hold!! It's useless to talk to donkeys to teach them the Bible!!
Black, you are fully aware of what happened to Geron!! And, perhaps such other companies. The advisory board of the FDA is stuffed with large-pharma agents and whenever a BT product being developed by a clinical-stage biotech comes along and if it challenges the product of the company the agent has ties with, it finds ways to bog down the licensing, perhaps apparently all through regulatory requirements compliance.
If you ever had to buy prescription drugs for your eyes, you would know how expensive those are - a drop may cost you a dollar or more!! Drug companies producing drugs for treatment of retinal disorders do not really want patients to get fully cured and cured fast so that they can keep shovelling money as much as they can!! For such a company the revolutionary RPE treatment can be a real challenge to its business and it will use any means to stall the treatment licensed fast. This happens especially in the USA due to the overwhelming influence of lobbies (thanks to money-hungry politicians). This is one reason why the Geron management must have thought it wise to join hands with JNJ before even they started Ph 2, despite the company having enough cash ($148M) in hand to go through Ph 2.
Institutional investors consider getting in when Ph 3 begins while watching the prospects. Until then retail traders, shorts and hedgies have a "field day" who keep the SP swinging like a yo-yo so that they can make their living by day trading. During this yo-yo phase, institutional hedgies manipulate share price perhaps with cooperation from the MM both of who help each other. Based on this understanding, you have to decide what is best for you. If you are not a trader and in for a long-term investment after having studied the company management and prospects for its products well, just keep adding to your portfolio when the SP hits its lows. Note that traders use charts and institutional traders/hedgies and MM are well versed in these techniques as well as psychology of retail shorts and traders to easily fool them or keep them guessing. It's always a tough sledding for retail monkeys.
What position did you work? Did you work in a position where you were required to deal directly with the FDA? Do you know how many cases were filed against the FDA for improper actions and the courts approved penalties against?
Smitty, the way your thoughts direct you, you will just say, "What the fXXX, I can do everything Obama or any US.President does"!! My advice: Find a decent plumbing job first, buddy!!
The US Ph 1/2 trials have already shown the breakthrough results of effectiveness and no serious side effects and yet the US FDA hasn't moved faster and grant it an FTD status so far. I am not saying it will not; all I am saying is that the Ocata being a U.S. company, the home agency must push it faster into the market than a foreign regulatory agency does!! But, the US FDA hasn't changed its policy to be soft to large pharmas and being a harassment to clinical-stage biotechs!! Do you disagree with it? Just see how the FDA has been treating Geron's Imetelstat licensing for low-grade liver issue (perhaps reversible) to already licensed Jakafi inhibitors produced by a large pharma producing several side effects, including the liver issue!! The same FDA!!!
These guys are sacred now that the SP is not going down anymore and may be beginning its upward climb!! So they are trying to brainwash idiots to believe their lies!! Desperation leads to frustration, and frustration leads to commit horrible deeds, like outright lying!! We should simply pity these pitiable folks, because they haven't learned their lesson yet!!!
With only 2M patients a year in the USA against 200-300M patients a year globally, should Ocata now really care if the US FDA drags its feet for licensing the RPE treatment for SMD/AMD patients since the EU agency has already moved much faster to licensing it? Let the US FDA get bogged down in the corrupt practice of looking for vested interests and lobby influence, Ocata is showing a way to other clinical stage biotechs to deal with the US FDA!!!
I can't believe he exited from Geron prematurely!! Perhaps he found greener ground somewhere else and is making more money there. I think he will be back in January!!
Thank you for correcting my spelling of "foul". This board is full of traders and shorts. No wonder the truth hurts you being a "bear" or "beare"?!
Black, click on his ID on any of his old posts and you will find that he is very active on other boards, meaning he may have taken his profits trading Geron and may have moved to ARWR and such other stocks. He is certainly a smart and wise trader who doesn't invest long term for any stock.
If you see Cramer's reasons for recommending stocks in his private letters to subscribers (I am not the one and will never that mistake to do so!), you will see easily that he is clearly a guy with simply accounting background who can't understand what fibrosis means or what is the telomerase concept. He is just a typical WS trader and manipulator. To expect Cramer to forecast value of IMET in the field of oncology is like asking a fool to explain the theory of relativity!!!